All news articles for November 2022

Pic:getty/kojofeja

BigHat Biosciences enters AI research collaboration with Merck

By Rachel Arthur

BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.

Pic:getty/morsaimages

Blue Water Vaccines to develop oral chlamydia vaccine

By Rachel Arthur

Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.

Pic:getty/dzmitrydzemidovich

Long-COVID personalized medicine enters Phase 2 trial

By Rachel Arthur

GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.

© GettyImages/Charday Penn

Oramed inks deal to commercialize oral insulin in South Korea

By Jane Byrne

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate....

Pic:getty/markrubens

BioNTech acquires GMP manufacturing site in Singapore

By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

Pic:getty/nicholasfree

EdiGene Biotechnology moves into new R&D center in Massachusetts

By Rachel Arthur

EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.

© GettyImages/PM Images

Most popular stories in October 2022

By Jane Byrne

Novo Nordisk, Sanofi, AstraZenec, Merck and Moderna, among others, feature in our round-up of top hitting stories last month.

Pic:getty/drmicrobe

Monoclonal antibody offers new way to protect against malaria

By Rachel Arthur

One dose of an antibody drug protected from malaria infection during the malaria season in Mali, showing up to 88% effectiveness: demonstrating for the first time that a monoclonal antibody can prevent malaria in an endemic region.

© GettyImages/Monty Rakusen

Lonza: N-1 perfusion capability enables increased process titers

By Jane Byrne

The biopharma sector has seen recent advancements in process intensification, especially in relation to upstream processing, with the technology employed aimed at increasing drug output. One of the quickest and simplest ways to achieve process intensification...

Pic:getty/andrewbrookes

FDA expected to make decision on GSK’s RSV vaccine in May

By Rachel Arthur

The US Food and Drug Administration (FDA) has granted Priority Review to GSK’s respiratory syncytial virus (RSV) older adult vaccine candidate with a decision expected in May 2023: which could make it the first vaccine approved against the virus.

Follow us

Products

View more

Webinars